Korro Bio is trading at $14.90, down 5.96% in premarket, with no confirmed catalyst.
- No fresh company-specific announcement was identified for November 3; the latest listed company press release is dated October 16.
- Nasdaq’s listed filings show no filing dated November 3; the latest listed filing is October 27.
- Supplied index readings do not show a broad market decline of more than 0.5% in the same direction. Premarket volume or activity data was not provided.